Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

785 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (Lille). The creation of this regional cohort, smaller than the national cohort of Biomarkers France, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. To increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated to this activity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

NCT01700582

Carcinoma, Non-Small-Cell Lung ALK Gene Mutation KRAS Gene Mutation +1 more

COMPLETED

A Clinico-biological Database of Lung Cancers

NCT03387865

Lung Cancer

RECRUITING

Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer

NCT04589013

Non-small Cell Lung Cancer

COMPLETED

Early Palliative Care in Metastatic Lung Cancer in Northern France

NCT02308865

Lung Cancer Metastatic

TERMINATED NA

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NCT02785562

Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform CRRC, except EGFR and KRAS treated from September 2011 to February 2013.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥ 18 years old
* Patient with non-small cell lung cancer
* Detected in the Nord Pas de Calais
* Monitored in the Nord Pas de Calais
* Patient must have signed a non-opposition form to the use of medical data